1. Basic Product Identification
Alectinib
INN Name: Alectinib
Brand Name: Alecensa®
Therapeutic Class: Targeted anticancer therapy
Pharmacological Class: ALK (Anaplastic Lymphoma Kinase) inhibitor
Dosage Form: Oral capsules
Primary Indication: ALK-positive non-small cell lung cancer (NSCLC)
2. Therapeutic Knowledge
Alectinib is used in:
First-line treatment of ALK-positive NSCLC
Treatment of metastatic lung cancer with ALK rearrangements
CNS metastases (brain penetration is a key advantage)
???? Clinical advantages:
Superior progression-free survival vs crizotinib
Strong CNS activity (crosses blood–brain barrier)
Better tolerability profile
3. Mechanism of Action (MOA)
Alectinib is a highly selective ALK tyrosine kinase inhibitor (TKI).
Mechanism:
Inhibits get more info ALK phosphorylation
Blocks downstream signaling pathways:
PI3K/AKT
MAPK pathway
???? Result:
Inhibition of tumor cell proliferation
Induction of apoptosis in ALK-driven cancer cells
Also inhibits:
RET kinase (minor off-target activity)
4. Pharmacokinetics (ADME)
Absorption: High oral absorption with food
Bioavailability: Improved with fat-containing meals
Tmax: ~4–6 hours
Protein binding: >99%
Metabolism: Hepatic (CYP3A4 → active metabolite M4)
Half-life:
Alectinib: ~32 hours
Metabolite M4: similar activity
Excretion: Fecal (~98%), minimal renal
⚠️ CYP3A interactions are clinically relevant
5. Dosage & Administration
Standard dose: 600 mg orally twice daily
Taken with food
Dose adjustment:
Liver impairment
Drug interactions (CYP3A inhibitors/inducers)
Monitoring:
Liver function tests
CPK levels (myopathy risk)
Lung function (pneumonitis risk)
6. Formulation Knowledge
Hard gelatin capsules
High-dose oral solid formulation
Challenges:
Low aqueous solubility
High lipophilicity
Food-dependent absorption
Excipients:
Lactose monohydrate
Microcrystalline cellulose
Sodium starch glycolate
Magnesium stearate
Capsule shell gelatin
7. Raw Materials Knowledge
API: Alectinib hydrochloride
Synthetic class:
Small molecule kinase inhibitor
Key intermediates:
Aromatic heterocycles
Benzamide derivatives
Critical raw material concerns:
Chirality control (if applicable in intermediates)
Polymorphic form consistency
High potency handling controls
8. Manufacturing Process Knowledge
API synthesis:
Multi-step organic synthesis
Heterocyclic ring formation
Final salt formation (HCl salt)
Purification via crystallization & chromatography
Capsule manufacturing:
Micronization (improves dissolution)
Blending with lubricants
Capsule filling under humidity control
Critical process controls:
Particle size distribution
Polymorph control
Content uniformity (high-dose oncology drug)
9. Analytical & QC Knowledge
Key QC tests:
HPLC assay (potency)
Related substances (impurity profiling)
Dissolution testing (critical for bioavailability)
Residual solvents (GC)
Polymorph identification (XRPD)
Content uniformity
Stability-indicating methods
Critical quality attributes (CQAs):
Dissolution rate
Impurity thresholds
Crystal form stability
10. Regulatory Knowledge
Approved globally for ALK-positive NSCLC
Classified as:
Targeted oncology therapy (TKI)
Regulatory requirements:
Companion diagnostic (ALK testing mandatory)
Oncology risk management plan
CNS efficacy data requirement
11. Storage & Stability
Store at 20–25°C
Protect from:
Moisture
Excess heat
Stable polymorphic form must be maintained
Stability risks:
Polymorphic conversion
Degradation under humidity
Photostability generally stable but still controlled
12. Packaging Knowledge
HDPE bottles with desiccant
Blister packs (Alu-Alu for moisture protection)
Child-resistant oncology packaging
Secondary packaging:
Oncology hazard labeling
Storage instructions (dry place critical)
13. Safety & Toxicology
Major adverse effects:
Hepatotoxicity (ALT/AST elevation)
Myalgia and CPK elevation
Constipation
Interstitial lung disease (rare but serious)
Bradycardia
Contraindications:
Severe liver impairment (dose adjustment required)
Monitoring:
Liver function
CPK
Pulmonary symptoms
14. Market & Commercial Knowledge
Competes with:
Crizotinib
Ceritinib
Brigatinib
Lorlatinib
Strengths:
Strong CNS penetration
Better survival outcomes
Market segment:
High-value oncology precision medicine
Pricing:
Premium targeted therapy market
15. Intellectual Property (IP)
Originator: Chugai / Roche
Patent protection:
Composition of matter (key patents still active in some regions)
Formulation + use patents
Biosimilar:
Not applicable (small molecule, but generic entry restricted by patents in some markets)
16. Environmental & EHS Knowledge
High-potency API handling required
Cytotoxic waste classification
Organic solvent recovery systems required
Worker safety:
PPE mandatory (oncology API exposure risk)
Closed-system manufacturing recommended
17. Export Documentation Knowledge
Required documents:
DMF (Drug Master File)
COA (API & finished product)
GMP certificate
Stability data (ICH)
Bioequivalence study reports
Polymorph characterization report
MSDS (cytotoxic handling classification)
Batch manufacturing records
18. Business Development Knowledge
Target buyers:
Oncology hospitals
Cancer specialty distributors
Government oncology programs (limited)
Strategy:
Precision oncology positioning
Companion diagnostic partnerships
Key value proposition:
CNS metastasis effectiveness
First-line ALK NSCLC therapy standard
19. Advanced Technical Knowledge
ALK fusion drives oncogenesis via constitutive kinase activation
Alectinib inhibits ATP-binding site of ALK kinase domain
Active metabolite (M4) contributes significantly to efficacy
CNS penetration is critical differentiator
Resistance mechanisms:
ALK secondary mutations (e.g., G1202R)
20. AI & Digital Knowledge (Modern Pharma)
Applications:
AI-driven mutation resistance prediction (ALK variants)
Radiology AI for CNS metastasis response tracking
Pharmacokinetic modeling for dose optimization
Real-world evidence (RWE) oncology analytics
Digital companion diagnostics integration
21. Sales Team Product Knowledge Checklist
Sales must know:
ALK-positive NSCLC indication only
Requires genetic testing (ALK fusion)
Twice daily dosing with food
Strong brain metastasis efficacy
Liver toxicity monitoring required
Not interchangeable with other TKIs
High-value precision oncology therapy
22. Most Important Technical Documents
DMF / CMC Module 3
Stability studies (ICH Q1A/Q1B)
Polymorph characterization report (XRPD)
Bioequivalence studies (generic)
Impurity profile report
Clinical efficacy data (ALK trials)
Drug–diagnostic co-development data
Manufacturing validation batch records
23. Ultimate Pharma Product Mastery Summary
Alectinib is:
A next-generation ALK tyrosine kinase inhibitor
Designed for precision oncology in ALK-positive NSCLC
Highly effective in brain metastases due to CNS penetration
A high-value, targeted cancer therapy with biomarker dependency
???? Strategic importance:
Core drug in precision oncology portfolios
High-margin specialty oncology product
Strong demand in biomarker-driven cancer treatment
Central to ALK-positive NSCLC standard of care